Equillium, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Equillium is a clinical-stage biotechnology company developing itolizumab (EQ001) for severe immuno-inflammatory diseases. It has no approved products and has generated no product revenue.
Financial results and liquidity
- Revenue and margins: No revenue was reported; profit and gross-margin measures are not applicable.
- Q2 expenses and loss: Research and development (R&D) expense was $6.0 million, up from $3.9 million; general and administrative expense was $2.9 million, versus $2.7 million. Total operating expenses were $8.8 million, up from $6.6 million. Net loss was $9.2 million, compared with $6.5 million; basic and diluted loss per share was $0.31 versus $0.37.
- First-half results: R&D expense was $11.9 million versus $8.6 million, and total operating expenses were $17.5 million versus $14.1 million. Net loss was $18.1 million versus $14.3 million; loss per share was $0.64 versus $0.81.
- Cash and investments: At June 30, cash and cash equivalents were $73.5 million and short-term investments were $24.1 million, totaling $97.6 million, compared with $82.2 million at December 31, 2020. Management said these resources were expected to fund planned operations for at least 12 months from the filing date.
- Cash flow: First-half operating cash use was $14.9 million, versus $11.5 million in 2020. Investing activities provided $33.8 million, mainly reflecting investment maturities; financing activities provided $30.7 million, primarily from the February registered direct offering. Cash increased $49.5 million during the period.
- Debt: Notes payable had a $10.1 million carrying value and mature June 1, 2024. The loans bear interest at the greater of 8.25% or prime plus 3.00%. Following achievement of a clinical milestone, interest-only payments were extended through June 30, 2022, followed by 24 monthly principal-and-interest payments. The company reported covenant compliance.
- Equity financing and dilution: The February 2021 registered direct offering generated $29.9 million net proceeds from 4.29 million shares and included warrants to purchase 1.29 million shares. Shares outstanding were 29.38 million at June 30, versus 24.75 million at year-end.
Material changes and management commentary
- Q2 R&D expense rose by $2.1 million year over year, principally due to higher employee compensation and increased clinical development activity in aGVHD and lupus/lupus nephritis. First-half R&D increased $3.3 million, with similar drivers.
- Management expects expenses and losses to increase as it advances clinical development. It expects to fund operations through available resources and, as needed, equity, debt, collaboration, or license arrangements; future financing may be unavailable, costly, or dilutive.
- In June, the company reported positive topline results from the Phase 1b portion of the EQUATE aGVHD study. After quarter-end, it reported that a July FDA End-of-Phase 1 meeting confirmed a path toward a single pivotal Phase 3 study; management planned to initiate that study in Q4 2021.
- Management planned to announce EQUIP asthma topline data and interim EQUALISE lupus nephritis data in the second half of 2021. Earlier COVID-19-related enrollment pauses in EQUIP and EQUALISE had been lifted, but the pandemic remained a risk to trial enrollment, timing, and operations.
- The Biocon license includes up to $30 million in regulatory milestones, up to $565 million in sales milestones, and royalties; no milestone or royalty payments had been made or received as of June 30, 2021.
Risks, contingencies, and other items
- The company has incurred recurring losses and negative operating cash flows, with an accumulated deficit of $89.1 million. It does not expect product-sale revenue within the next 12 months, if ever.
- Clinical development, regulatory outcomes, manufacturing, and COVID-19 disruption could delay or prevent development and approval. Failure to obtain additional capital when required could force program delays, reductions, or termination.
- Loan documents restrict additional indebtedness without lender consent. The debt also includes a 5% final payment fee and prepayment fees under specified conditions.
- The company reported no legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements. Management concluded disclosure controls were effective at a reasonable assurance level.
Key facts for investors to verify
- Whether the planned Q4 2021 pivotal aGVHD Phase 3 trial was initiated, and its design, enrollment, cost, and timeline.
- Results and timing of the planned EQUIP asthma and EQUALISE lupus nephritis updates, including any pandemic-related delays.
- Actual cash burn and remaining runway as clinical spending increases, and the availability and terms of additional financing.
- Potential dilution from outstanding warrants, options, and future equity offerings, as well as the debt repayment schedule and covenant requirements.
- Whether development progress triggers additional Biocon obligations or changes the economics and scope of the licensed rights.